Nomura Holdings Inc Nurix Therapeutics, Inc. Transaction History

Nomura Holdings Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$8.7 - $13.28 $1.38 Million - $2.11 Million	-158,800 Reduced 54.98%	130,040 $1.3 Million
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $35,429 - $54,883	4,139 Added 1.45%	288,840 $2.56 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $458,460 - $678,391	46,497 Added 19.52%	284,701 $3.12 Million
Q3 2022 Nov 15, 2022	SELL	$12.33 - $19.81 $835,937 - $1.34 Million	-67,797 Reduced 22.16%	238,204 $3.1 Million
Q2 2022 Aug 15, 2022	BUY	$7.88 - $14.82 $5,208 - $9,796	661 Added 0.22%	306,001 $4.06 Million
Q1 2022 May 18, 2022	BUY	$12.94 - $29.65 $1.67 Million - $3.82 Million	128,674 Added 72.83%	305,340 $4.27 Million
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $2.12 Million - $2.77 Million	80,316 Added 83.36%	176,666 $5.15 Million
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $1.52 Million - $2.46 Million	67,010 Added 228.39%	96,350 $3 Million
Q2 2021 Aug 16, 2021	SELL	$24.21 - $35.89 $2.42 Million - $3.59 Million	-99,900 Reduced 77.3%	29,340 $786,000
Q1 2021 May 17, 2021	BUY	$26.98 - $50.17 $3.49 Million - $6.48 Million	129,240 New	129,240 $4.01 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.